Abstracts Archive - Page 1592 of 2607 - ACR Meeting Abstracts

Abstract Number: 8 • 2017 Pediatric Rheumatology Symposium
Examination of Reported Risk Loci from Candidate Gene Studies of Systemic Juvenile Idiopathic Arthritis Identifies Link between IL1RN Variation and both Disease Susceptibility and Response to Interleukin-1 Directed Therapy
Victoria Arthur¹, Emily Shuldiner¹, Anne Hinks², The International Childhood Arthritis Genetics (INCHARGE) Consortium³, Patricia Woo⁴, Wendy Thomson², Elaine F. Remmers⁵ and Michael J. Ombrello¹, ¹Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD, ²Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ³INCHARGE Consortium, Bethesda, MD, ⁴Paediatric Rheumatology Unit, University College London, London, United Kingdom, ⁵Inflammatory Disease Section, NHGRI, NIH, Bethesda, MD
Background/Purpose: Systemic JIA (sJIA) is a childhood inflammatory disease whose pathophysiology is poorly understood. sJIA is phenotypically heterogeneous with variable manifestations and responses to treatment.…
Abstract Number: 18 • 2017 Pediatric Rheumatology Symposium
Bridging the gap between GWAS and mechanism in juvenile idiopathic arthritis using a novel high-throughput experimental screen
Gang Li¹, Marta Martinez-Bonet¹, Di Wu², Jing Cui³ and Peter A. Nigrovic^1,4, ¹Brigham and Women's Hospital, Boston, MA, ²University of North Carolina, Chapel Hill, Chapel Hill, NC, ³Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Genome wide association studies (GWAS) have identified 27 non-HLA loci that convey risk for oligoarticular and seronegative polyarticular JIA. Most associated haplotypes bear no…
Abstract Number: 85 • 2017 Pediatric Rheumatology Symposium
Characteristics of anti-MDA5 autoantibody-associated Juvenile Dermatomyositis (JDM) in North America
Gulnara Mamyrova¹, Takayuki Kishi², Ira N Targoff³, Rodolfo V Curiel¹, Frederick W Miller², Lisa G Rider^1,2 and The Childhood Myositis Heterogeneity Collaborative Study Group, ¹Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institute of Health, Bethesda, MD, ³VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Anti-MDA5 Abs have been reported to associate with clinically amyopathic and classic dermatomyositis (DM), with severe progressive interstitial lung disease (ILD) and poor prognosis…
Abstract Number: 157 • 2017 Pediatric Rheumatology Symposium
Utility of Mailed Reminders for Uveitis Screening Guidelines in Patients with Juvenile Idiopathic Arthritis
Laura Ballenger¹ and Kyla Driest², ¹Nationwide Children's Hospital, Columbus, OH, ²Rheumatology, Nationwide Children's Hospital, Columbus, OH
Background/Purpose: Uveitis is a major complication in patients with juvenile idiopathic arthritis (JIA) and can be completely asymptomatic until vision loss develops. In order to…
Abstract Number: 72 • 2017 Pediatric Rheumatology Symposium
Systemic Juvenile Idiopathic Arthritis in a Colombian cohort: onset and clinical course
Angela Mosquera, Clara Malagón and Christine Arango, Pediatric Rheumatology, Pediatric rheumatology post graduate program El Bosque University, Bogota, Colombia
Background/Purpose: Juvenile idiopathic arthritis is the most prevalent rheumatic disease in children. The systemic form accounts for 10-15% of cases and is characterized by a…
Abstract Number: 40 • 2017 Pediatric Rheumatology Symposium
Perspectives of young people with Juvenile Idiopathic Arthritis, their caregivers, and health care providers on transition to adult care: Informing development of a transition toolkit
Nadia Luca¹, Evelyn Rozenblyum², April Elliott³, Lynn R. Spiegel⁴, Nicole Johnson⁵, Sara Ahola Kohut⁶, Yvonne Brandelli³, Carolyn Johns⁷, Stephanie Luca⁸, Dianne P. Mosher⁹, Gordon Soon¹⁰, Karine Toupin-April¹¹, Gabriela Uifalusi³ and Jennifer N. Stinson¹², ¹Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ²Royal University Hospital, Saskatoon, SK, Canada, ³Alberta Children's Hospital, Calgary, AB, Canada, ⁴Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Pediatrics, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ⁶Hospital for Sick Children, Toronto, ON, Canada, ⁷Alberta Health Services, Calgary, AB, Canada, ⁸The Hospital for Sick Children, Toronto, ON, Canada, ⁹Med, University of Calgary, Calgary, AB, Canada, ¹⁰Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ¹¹Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ¹²Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: A seamless transition from pediatric to adult care is critical to ensure optimal health outcomes in adolescents and young adults with Juvenile Idiopathic Arthritis…
Abstract Number: 47 • 2017 Pediatric Rheumatology Symposium
Baseline characteristics of the first 123 patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA comparative effectiveness study
Sarah Ringold¹, George A. Tomlinson², Pamela F. Weiss³, Laura E. Schanberg⁴, Brian M. Feldman⁵, Mary Ellen Riordan⁶, Anne C. Dennos⁷, Vincent Del Gaizo⁸, Kate Murphy⁹, Yukiko Kimura⁶ and the CARRA Registry Investigators, ¹Seattle Children's Hospital, Seattle, WA, ²Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Pediatrics, Duke Medical Center, Durham, NC, ⁵Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁶Hackensack University Medical Center, Hackensack, NJ, ⁷Duke Clinical Research Institute, Durham, NC, ⁸Parent Partner, Whitehouse Station, NJ, ⁹Patient Partner, San Francisco, CA
Background/Purpose: Many new effective treatments for polyarticular JIA (p-JIA) are available, but there is significant variation among pediatric rheumatologists in the timing of when biologic…
Abstract Number: 105 • 2017 Pediatric Rheumatology Symposium
Isolated Pediatric Pulmonary Capillaritis: A Comprehensive Single-Center Review of Disease Course, Management, and Prognosis
William Lapin¹, Saimun Singla², Eyal Muscal³ and Manuel Silva-Carmona⁴, ¹Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Department Pediatrics, Division of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Department of Pediatrics, Pulmonology Section, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Pediatric diffuse alveolar hemorrhage (DAH) is a life-threatening disorder characterized by pulmonary hemorrhage and respiratory insufficiency. Histologically, DAH with capillary inflammation is known as…
Abstract Number: 124 • 2017 Pediatric Rheumatology Symposium
Underutilization of Social Workers for Mental Health Care of Adolescents in Pediatric Rheumatology: A Mixed Methods Study
Andrea Knight^1,2, Michelle Vickery³, Lauren Faust⁴, Eyal Muscal⁵, Alaina M. Davis⁶, Julia Harris⁷, Aimee O. Hersh⁸, Martha Rodriguez⁹, Karen Onel¹⁰, Laura E. Schanberg¹¹, Tamar Rubinstein¹², Nina Washington^13,14, Elissa Weitzman^15,16, Hana Conlon¹⁷, Dana Gerstbacher¹⁸, Jennifer Woo¹⁹ and Emily Von Scheven²⁰, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Center for Pediatric Clinical Effectiveness & PolicyLab, Philadelphia, PA, ³PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁶Pediatric Rheumatology, Monroe Carell Junior Children's Hospital at Vanderbilt, Division of Pediatric Rheumatology, Nashville, TN, ⁷Children's Mercy Kansas City, Kansas City, MO, ⁸Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT, ⁹Pediatrics, University of Chicago Medical Center, Chicago, IL, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Pediatrics, Duke Medical Center, Durham, NC, ¹²Albert Einstein College of Medicine, Children's Hospital at Montefiore, New York, NY, ¹³University of Mississippi Medical Center, Jackson, MS, ¹⁴Dept. of Pediatric Rheumatology, University of Mississippi Medical Center, Jackson, MS, ¹⁵Boston Children's Hospital, Boston, MA, ¹⁶Harvard Medical School, Boston, MA, ¹⁷Columbia University, New York, NY, ¹⁸Stanford University, Palo Alto, CA, ¹⁹University of California Los Angeles, Los Angeles, CA, ²⁰Dept of Pediatric Rheumatology, Univ of California San Francisco, San Francisco, CA
Background/Purpose: Mental health problems are common, but undertreated in adolescents with rheumatologic conditions. As social workers help manage medical and psychosocial aspects of illness, we…
Abstract Number: 35 • 2017 Pediatric Rheumatology Symposium
Kv1.3 Expression on Urinary Leukocytes in Lupus Nephritis: Potential for Targeted Immunotherapy
Anne Stevens¹, Andrew Hinkle², Megan Yuasa³, David Peckham⁴, Chelsea Olsen⁵, Craig Philips⁵, Shawn P. Iadonato⁴ and Peter Probst⁶, ¹University of Washington, Pediatrics, Seattle, WA, ²Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, ³Seattle Children’s Research Institute, Seattle, WA, ⁴Kineta Inc, Seattle, WA, ⁵KPI Therapeutics, Inc., Seattle, WA, ⁶Kineta, Inc, Seattle, WA
Background/Purpose: Lymphocyte activation depends upon a calcium signaling cascade that is regulated by voltage-gated potassium channels. Effector memory T cells (TEM), which are implicated in…
Abstract Number: 133 • 2017 Pediatric Rheumatology Symposium
3-D Explant Method Facilitates the Study of Lymphocytes in Synovium and Reveals a Population of Resident Memory-Like T Cells in Rheumatoid Arthritis
Lauren Henderson¹, Deepak Rao², Nikola Teslovich^3,4, Sandra King⁵, Fumitaka Mizoguchi⁶, Sarah Ameri⁶, Allyn Morris⁷, Christopher Elco⁵, Margaret Chang⁸, Anais Levescot⁹, James Lederer¹⁰, Scott Martin¹¹, Barry Simmons¹¹, John Wright¹¹, Michael Brenner², Soumya Raychaudhuri^{12,13,14,15,16}, Robert Fuhlbrigge¹⁷ and Peter Nigrovic^1,18, ¹Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Program in Medical and Population Genetics, Broad Institute of Massachusetts Technical Institute and Harvard University, Cambridge, MD, ⁴Divisions of Genetics and Rheumatology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁵Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁷Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ⁸Division of Immunology, Boston Children's Hospital, Boston, MA, ⁹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, boston, MA, ¹⁰Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ¹¹Department of Orthopedic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹²Divisions of Genetics and Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ¹³Program in Medical and Population Genetics, Broad Institute of Massachusetts Technical Institute, Harvard University, Cambridge, MA, ¹⁴Partners Center for Personalized Genetic Medicine, Boston, MA, ¹⁵Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom, ¹⁶Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden, ¹⁷Children's Hospital Colorado, Aurora, CO, ¹⁸Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Tissue resident memory T (TRM) cells survive indefinitely in barrier tissues and mediate swift immunologic memory responses at sites of microbe entry. TRM cells…
Abstract Number: 25 • 2017 Pediatric Rheumatology Symposium
Reliability of the Physician Global Assessment Scores for Determination of Disease Activity Status within the Pediatric Rheumatology Care and Outcomes Improvement Network
Brandt Groh¹, Ottar Kristinsson², Lisabeth V. Scalzi³, C. April Bingham⁴, Ronald Laxer⁵, Cagri Yildirim-Toruner⁶, Esi Morgan⁷, Michelle Batthish⁸, Beth Gottlieb⁹, Julia G. Harris¹⁰, Murray Passo¹¹, Michael Shishov¹² and Sheetal S. Vora¹³, ¹Pediatrics, Penn State Milton S. Hershey Medical Center, Hershey, PA, ²Pediatrics, Penn State Children's Hospital, Hershey, PA, ³Department of Rheumatology, Penn State Hershey Children’s Hospital, Hershey, PA, ⁴Penn State Health Children's Hospital, Hershey, PA, ⁵Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁷Pediatric rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, ⁹Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ¹⁰Children's Mercy - Kansas City, Kansas City, MO, ¹¹Division of Rheumatology PTD, Medical University of South Carolina, Charleston, SC, ¹²Pediatric Rheumatology, Phoenix Children's Hospital, Phoenix, AZ, ¹³Pediatric Rheumatology, Levine Children's Hospital, Charlotte, NC
Background/Purpose: Within the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN), the Physician Global Assessment (PhGA) metric is a key determinant of Òclinically inactiveÓ juvenile…
Abstract Number: 107 • 2017 Pediatric Rheumatology Symposium
Children with Relapsing Polychondritis are likely to be seen in the emergency room prior to establishing the diagnosis
Marcela Ferrada¹, Ninet Sinaii², Keith A. Sikora³, Peter C. Grayson⁴, Thomas Christie⁵, Robert Colbert⁴ and James D. Katz⁶, ¹NIAMS, National Institues of Health, Bethesda, MD, ²Clinical Center, National Institutes of Health, Bethesda, MD, ³Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵Relapsing Polychondritis Awareness and Support Foundation, Anoka, MN, ⁶NIAMS, National Institutes of Health, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a rare immune-mediated disease characterized by recurrent episodes of chondritis. The pathogenesis of RP is poorly understood, and clinical manifestations…
Abstract Number: 76 • 2017 Pediatric Rheumatology Symposium
Applying 2016 MAS Criteria to Systemic onset Juvenile Idiopathic Arthritis Patients with Diagnosis of Macrophage Activation Syndrome
Ezgi Baris^1,2, Edwin Anderson³ and Fatma Dedeoglu¹, ¹Division of Immunology, Rheumatology Program, Boston Children's Hospital, Harvard Medical School, Boston, MA, ²Pediatrics, Marmara University, Istanbul, Turkey, ³Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Macrophage activation syndrome (MAS) is the result of uncontrolled systemic inflammation, which can sometimes complicate systemic onset juvenile idiopathic arthritis (SoJIA). MAS classification criteria…
Abstract Number: 154 • 2017 Pediatric Rheumatology Symposium
“Celebrate Ability”: Structured Art Workshop as a Therapeutic Coping Strategy for Patients with Juvenile Idiopathic Arthritis
Anastasia Dropol¹, Michael Lang², Susanne Benseler¹, Tommy Gerschman³, Nicole Johnson³, Jewel Loewen⁴, Nadia Luca¹, Alicia Ponzio², Brian Rusted⁵, Heinrike Schmeling⁶, Rebeka Stevenson³, Leeanne Stringer², Marinka Twilt¹ and Paivi Miettunen³, ¹Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ²University of Calgary, Calgary, AB, Canada, ³Pediatrics, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ⁴Pediatrics, University of Calgary, Calgary, AB, Canada, ⁵Fine Arts, University of Calgary, Calgary, AB, Canada, ⁶University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) affects nearly 20,000 Canadian children. Despite success with medications, managing “invisible” symptoms such as pain and fatigue and psychosocial limitations…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].